FREE LIVE WEBINARS FOR
MEMBERS & NON MEMBERS

Each month, the NATA scientific committee organises a one-hour interactive session led by top experts, featuring a hot topic related to clinical practice.

Registered participants can submit questions during the session.

UPCOMING WEBINAR

Table of Contents

Iron across cardiac disease where we have come from in heart failure and heart surgery?

Date: 19 November

Time: 18:00 – 19:00 CET

Experts

Stefan D.  ANKER

Professor of Cardiology & Metabolism, Charité – Universitätsmedizin Berlin
Professor of Tissue Homeostasis in Cardiology, Berlin Institute of Health (BIH)
Principal Investigator, German Centre for Cardiovascular Research (DZHK)

Toby RICHARDS MD FRCS FRACS DipPOM

Professor of Surgery, School of Health, Sport & Bioscience UEL

Hon. Professor Institute of Clinic Trials and Methodology UCL

Hon. Professor Department of Anaesthesia & Perioperative Medicine Monash University

Learning Objectives
  •  The ideal definition of Iron Deficiency
  •  When to give IV iron
  •  Understand iron and muscle function

 

Supported by an unrestricted educational grant from Pharmacosmos 

PAST WEBINARS - WATCH THE REPLAYS

2026

Webinars 2026

7 Videos
Your questions answered

Following our webinar on Heparin-induced thrombocytopenia (HIT), Prof. Gabor Erdoës has provided answers to several questions raised during the session, addressing important aspects of HIT diagnosis and management.

How long do HIT antibodies remain in circulation after heparin is discontinued, and when should testing be performed to obtain the most reliable results?

HIT antibodies usually disappear over weeks to months. The median time to a negative functional assay, which detects platelet-activating antibodies, is approximately 50 days, compared with 85 days for an immunoassay, which detects antibody binding. These are population estimates, and antibody persistence varies considerably between individuals.

For diagnosis, test as soon as HIT is clinically suspected; there is no need to wait after stopping heparin. Interpret an IgG-specific PF4/heparin immunoassay alongside clinical probability and, where indicated, a functional assay such as SRA or HIPA. Treatment should not be delayed while awaiting confirmation when clinical suspicion is sufficiently high. If the question is whether heparin can be used again for cardiac surgery, repeat testing should establish the current antibody status. Elapsed time alone is less reliable.

Is fondaparinux indicated for the treatment of HIT?

Yes, fondaparinux is a guideline-supported treatment option, although its use for HIT is generally off-label. It is particularly useful in clinically stable patients with adequate renal function. In critically ill patients, those with substantial bleeding risk, or those likely to require urgent procedures, a shorter-acting intravenous agent such as argatroban or bivalirudin is usually preferable. Fondaparinux is renally cleared and should generally be avoided when creatinine clearance is below 30 mL/min because of the risk of accumulation and bleeding.

What is your approach to platelet transfusion in patients with HIT, particularly in the presence of bleeding?

I would avoid routine prophylactic platelet transfusion merely to correct the platelet count. However, HIT is not an absolute contraindication to platelet transfusion: clinically significant active bleeding or an urgent procedure with a high bleeding risk can justify transfusion. Life-threatening bleeding should not go untreated because of the HIT diagnosis.

In practice, I would assess whether thrombocytopenia is contributing to the bleeding and simultaneously investigate surgical bleeding, excessive anticoagulation, fibrinogen deficiency, and other coagulopathies. The aim is hemostasis rather than normalization of the platelet count. Any temporary interruption of anticoagulation requires frequent reassessment because HIT remains strongly prothrombotic.

Does the same apply to low-molecular-weight heparin?

Yes. Low-molecular-weight heparin (LMWH) can cause immune HIT, although the risk is substantially lower than with unfractionated heparin. Once HIT develops, switching from unfractionated heparin to LMWH is inappropriate because HIT antibodies commonly cross-react. Both forms of heparin must be discontinued, and a non-heparin anticoagulant must be used. The diagnostic and treatment principles are otherwise the same.

How would you manage an urgent heart-transplant candidate on ECMO and bivalirudin when a donor becomes available?

The decisive issue is the current platelet-activating antibody status, alongside bleeding risk, organ function, and the center’s experience. I would establish a joint plan with cardiac surgery, cardiac anesthesia, perfusion, hematology, and transfusion medicine:

If the functional assay is negative, intraoperative heparin for cardiopulmonary bypass, followed by protamine reversal, is supported, even if the immunoassay remains positive.

If the functional assay remains positive, bivalirudin during bypass is an established option in experienced centers. Alternatively, plasma exchange, with or without intravenous immunoglobulin (IVIG), can facilitate intraoperative heparin use.

After cardiac surgery, use a non-heparin anticoagulant when anticoagulation is required, particularly with active HIT or ongoing ECMO, and monitor for recurrent thrombocytopenia and thrombosis after any heparin re-exposure.

The 2026 ISTH guidance identifies bivalirudin as having the strongest supporting data, but no universally superior strategy exists. Bivalirudin requires a dedicated bypass protocol, including avoidance of stagnant blood in the circuit.

The existing bivalirudin infusion for ECMO cannot simply be assumed to provide adequate bypass anticoagulation. The lack of a reversal agent for bivalirudin also matters when planning hemostasis.

Plasma exchange ± IVIG: albumin or plasma, and when? Is it recommended by ASFA?

ASFA includes HIT-related plasma exchange as Category III, grade 2C: its optimal role is not established, and decisions should be individualized. This supports selected use rather than routine treatment of every patient with HIT.

Both albumin and plasma are acceptable replacement fluids. Plasma may be preferable immediately before cardiac surgery because it replaces coagulation factors and supplies immunoglobulins that may inhibit antibody-mediated platelet activation. Albumin-based exchange can reduce coagulation-factor levels. ASFA describes exchanges of approximately 1-1.5 total plasma volumes. There is no universally validated number of exchanges or timing schedule: published approaches range from one exchange immediately before surgery or intraoperatively before bypass to several exchanges over the preceding days. Timing should be coordinated with planned heparin exposure and, where available, functional testing. IVIG can complement antibody removal by inhibiting antibody-mediated platelet activation. If IVIG is combined with plasma exchange, it should generally be administered after the final planned exchange to avoid removing the infused immunoglobulin. Evidence remains largely observational. Neither an arbitrary number of exchanges nor a lower immunoassay value guarantees safe heparin re-exposure.

2025

Webinars 2025

9 Videos

2024

Webinars 2024

8 Videos

2023

Webinars 2023

9 Videos

2022

Webinars 2022

2 Videos

24H PBM MARATHONS

Stay Tuned about the next Webinar

Consent Management Platform by Real Cookie Banner